AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) - Share price

Stock Report

AcelRx Pharmaceuticals Inc ACRX

Cash Flow
Cash Flows From Operating Activities
Net Income-----
Depreciation and amortization1.982.051.740.581.67
Deferred income taxes-----
Accounts receivable-4.07-2.983.911.94-0.05
Account payable-----
Other working capital0.112.40-1.13-0.18-0.46
Other non-cash items-17.51-29.18-35.21-31.52-48.94
Net cash provided by operating activities-19.95-29.40-29.77-29.08-51.18
Cash Flows From Investing Activities
Investment in property, plant and equipment-1.46-3.72-2.41-0.82-3.47
Acquisitions Net-----
Purchases of investments-7.27-1.00-7.57-30.56-100.07
Sales/Maturities of investments16.936.53-20.5066.98
Purchases of intangibles-----
Other investing activities0.
Net cash used for investing activities8.201.81-9.97-10.88-36.56
Cash Flows From Financing Activities
Common stock issued--15.6981.531.23
Other financing activities59.63-0.03-3.37-6.5013.22
Net cash provided by (used for) financing activities59.63-0.0312.3375.0314.45
Net Change in Cash47.88-27.61-27.4135.07-73.29
Cash at beginning of period60.04107.9280.3153.0887.98
Cash at end of period107.9280.3152.9088.1514.68
Free cash in flow
Operating Cash Flow-19.95-29.40-29.77-29.08-51.18
Capital Expenditure-1.46-3.72-2.41-0.82-3.47
Free Cash Flow-21.41-33.12-32.17-29.89-54.65

Figures in millions. Currency is USD.

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2020 Morningstar. All rights reserved.